The acetyl-CoA carboxylase enzyme: a target for cancer therapy?

References

• Warburg O. On the origin of cancer cells. Science 1956;123(3191):309-14
   PubMed Web of Science ®Google Scholar
• Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004;23(18):3180-8
   PubMedGoogle Scholar
• Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006;25(48):6423-35
   PubMed Web of Science ®Google Scholar
• Voeller D, Rahman L, Zajac-Kaye M. Elevated levels of thymidylate synthase linked to neoplastic transformation of mammalian cells. Cell Cycle 2004;3(8):1005-7
   PubMed Web of Science ®Google Scholar
• Rahman L, Voeller D, Rahman M, et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5(4):341-51
   PubMed Web of Science ®Google Scholar
• Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16(3):202-8
   PubMed Web of Science ®Google Scholar
• Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13(1):27-9
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Piantadosi S, Pasternack GR. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 1989;321(10):636-41
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 1994;91(14):6379-83
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp (Warsz) 2004;52(6):414-26
   Google Scholar
• Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9(4):358-65
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 2006;9(4):346-57
   Google Scholar
• Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66(12):5977-80
   PubMed Web of Science ®Google Scholar
• Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem 2011;54(16):5615-38
   PubMed Web of Science ®Google Scholar
• Brownsey RW, Boone AN, Elliott JE, et al. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 2006;34(Pt 2):223-7
   PubMedGoogle Scholar
• Fullerton MD, Galic S, Marcinko K, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med 2013;19(12):1649-54
   PubMed Web of Science ®Google Scholar
• Postic C, Dentin R, Denechaud PD, et al. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr 2007;27:179-92
   PubMedGoogle Scholar
• Yahagi N, Shimano H, Hasegawa K, et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer 2005;41(9):1316-22
   PubMed Web of Science ®Google Scholar
• Iizuka K, Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J 2008;55(4):617-24
   PubMed Web of Science ®Google Scholar
• Campa D, McKay J, Sinilnikova O, et al. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. Breast Cancer Res Treat 2009;118(3):565-74
   Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7(2):168-81
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett 2010;20(12):3467-74
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9(10):2877-88
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 1998;95(13):7608-13
   PubMed Web of Science ®Google Scholar
• Svastova E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577(3):439-45
   PubMed Web of Science ®Google Scholar
• Moreau K, Dizin E, Ray H, et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 2006;281(6):3172-81
   PubMed Web of Science ®Google Scholar
• Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 2008;283(6):3418-23
   PubMed Web of Science ®Google Scholar
• Balendiran GK, Martin HJ, El-Hawari Y, et al. Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact 2009;178(1-3):134-7
   Google Scholar
• Patterson CE, Davis KS, Beckman DE, et al. Fatty acid synthesis in the fetal lung: relationship to surfactant lipids. Biochim Biophys Acta 1986;878(1):110-26
   Google Scholar
• Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, et al. Glucose avidity of carcinomas. Cancer Lett 2009;276(2):125-35
   PubMed Web of Science ®Google Scholar
• Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010;1805(2):141-52
   PubMed Web of Science ®Google Scholar
• Milgraum LZ, Witters LA, Pasternack GR, et al. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997;3(11):2115-20
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Zhan R, Wang Y, et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 2006;66(11):5934-40
   Google Scholar
• Brusselmans K, De Schrijver E, Verhoeven G, et al. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005;65(15):6719-25
   PubMed Web of Science ®Google Scholar
• Witters LA, Widmer J, King AN, et al. Identification of human acetyl-CoA carboxylase isozymes in tissue and in breast cancer cells. Int J Biochem 1994;26(4):589-94
   PubMedGoogle Scholar
• Olsen AM, Eisenberg BL, Kuemmerle NB, et al. Fatty acid synthesis is a therapeutic target in human liposarcoma. Int J Oncol 2010;36(5):1309-14
   PubMed Web of Science ®Google Scholar
• Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res 2007;67(17):8180-7
   PubMed Web of Science ®Google Scholar
• Supplemental Material. Available from: http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr17%3A35441927-35766902&hgsid=387917051_BE7hkKFJKYAhBwIkaTVnbfSv7xu6 and http://genome.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr17%3A80036214-80056208&hgsid=387917117_fbOFfw8KTVXWmQFtFFRHlAUdHefw
   Google Scholar
• Shah US, Dhir R, Gollin SM, et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol 2006;37(4):401-9
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7(10):763-77
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88(2):176-9
   PubMed Web of Science ®Google Scholar
• Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001;285(2):217-23
   PubMed Web of Science ®Google Scholar
• Magnard C, Bachelier R, Vincent A, et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 2002;21(44):6729-39
   PubMed Web of Science ®Google Scholar
• Sinilnikova OM, Ginolhac SM, Magnard C, et al. Acetyl-CoA carboxylase alpha gene and breast cancer susceptibility. Carcinogenesis 2004;25(12):2417-24
   Google Scholar
• Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 2003;63(21):7330-7
   PubMed Web of Science ®Google Scholar
• Lee J, Walsh MC, Hoehn KL, et al. Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity. J Immunol 2014;192(7):3190-9
   Google Scholar
• Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144(12):5179-83
   PubMed Web of Science ®Google Scholar
• Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116(7):1776-83
   PubMed Web of Science ®Google Scholar
• Luo Z, Saha AK, Xiang X, et al. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26(2):69-76
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Furukawa K, Hamamura K, et al. Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: induction of the lipogenic pathway by a melanoma antigen. Cancer Res 2011;71(14):4989-97
   Google Scholar
• Wang C, Chi Y, Li J, et al. FAM3A activates PI3K p110alpha/Akt signaling to ameliorate hepatic gluconeogenesis and lipogenesis. Hepatology 2014;59(5):1779-90
   PubMed Web of Science ®Google Scholar
• Pisonero-Vaquero S, García-Mediavilla MV, Jorquera F, et al. Modulation of PI3K-LXRalpha-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin. Lab Invest 2014;94(3):262-74
   PubMed Web of Science ®Google Scholar
• Scaglia N, Chisholm JW, Igal RA. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS One 2009;4(8):e6812
   PubMed Web of Science ®Google Scholar
• Ghillebert R, Swinnen E, Wen J, et al. The AMPK/SNF1/SnRK1 fuel gauge and energy regulator: structure, function and regulation. FEBS J 2011;278(21):3978-90
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67(22):10804-12
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66(21):10269-73
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27(25):3576-86
   PubMed Web of Science ®Google Scholar
• Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67(14):6745-52
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol 2010;116(1):92-8
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110(2):246-50
   PubMed Web of Science ®Google Scholar
• Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007;64(10):1290-302
   Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296(5573):1655-7
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9(8):550-62
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7(4):261-9
   PubMed Web of Science ®Google Scholar
• Currie RA, Walker KS, Gray A, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999;337(Pt 3):575-83
   PubMedGoogle Scholar
• Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24(50):7465-74
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30(2):193-204
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554
   PubMed Web of Science ®Google Scholar
• Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61(20):7426-9
   PubMed Web of Science ®Google Scholar
• Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 2010;347:21-41
   PubMed Web of Science ®Google Scholar
• Kang S, Denley A, Vanhaesebroeck B, et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci USA 2006;103(5):1289-94
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65(11):4562-7
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103(5):1475-9
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-7
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21(1):99-102
   PubMed Web of Science ®Google Scholar
• Shoji K, Oda K, Nakagawa S, et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 2009;101(1):145-8
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15(4):356-62
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441(7092):424-30
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497-510
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 2011;140(3):1071-83
   PubMed Web of Science ®Google Scholar
• Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336(6083):918-22
   PubMed Web of Science ®Google Scholar
• Kapur P, Rakheja D, Roy LC, et al. Fatty acid synthase expression in cutaneous melanocytic neoplasms. Mod Pathol 2005;18(8):1107-12
   Google Scholar
• Pizer ES, Thupari J, Han WF, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000;60(2):213-18
   PubMed Web of Science ®Google Scholar
• Chajes V, Cambot M, Moreau K, et al. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006;66(10):5287-94
   PubMed Web of Science ®Google Scholar
• Yan C, Wei H, Minjuan Z, et al. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells. PLoS One 2014;9(5):e97697
   Google Scholar
• Guseva NV, Rokhlin OW, Glover RA, et al. TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther 2011;12(1):80-5
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Elliott VA, Rychahou P, et al. Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. Carcinogenesis 2014;35(6):1341-51
   Google Scholar
• Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26(35):5713-20
   PubMed Web of Science ®Google Scholar
• Algire C, Amrein L, Zakikhani M, et al. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010;17(2):351-60
   Google Scholar
• Luo DX, Peng XH, Xiong Y, et al. Dual role of insulin-like growth factor-1 in acetyl-CoA carboxylase-alpha activity in human colon cancer cells HCT-8: downregulating its expression and phosphorylation. Mol Cell Biochem 2011;357(1-2):255-62
   Google Scholar
• Gansler TS, Hardman W3rd, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28(6):686-92
   PubMed Web of Science ®Google Scholar
• Rahman MT, Nakayama K, Rahman M, et al. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Br J Cancer 2012;107(2):300-7
   Google Scholar
• Rahman MT, Nakayama K, Ishikawa M, et al. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer. Oncology 2013;84(3):166-73
   Google Scholar
• Uddin S, Siraj AK, Al-Rasheed M, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008;93(10):4088-97
   Google Scholar
• Zhou Y, Niu C, Li Y, et al. Fatty acid synthase expression and esophageal cancer. Mol Biol Rep 2012;39(10):9733-9
   Google Scholar
• Orita H, Coulter J, Tully E, et al. High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biol Ther 2010;10(6):549-54
   PubMed Web of Science ®Google Scholar
• Ueda SM, Mao TL, Kuhajda FP, et al. Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93. Am J Pathol 2009;175(6):2618-24
   Google Scholar
• Haase D, Schmidl S, Ewald C, et al. Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 2010;12(8):844-54
   Google Scholar
• Fang W, Cui H, Yu D, et al. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol 2014;31(7):15
   Web of Science ®Google Scholar